Baralgetas ampoules instructions for use. What helps Baralgetas? Instructions for use. Method of application and dosage

Baralgetas: instructions for use and reviews

Latin name: baralgetas

ATX code: A03DA02

Active substance: metamizole sodium + pitofenone + fenpiverinium bromide (metamizole sodium + pitofenone + fenpiverinium bromide)

Manufacturer: JUGOREMEDIJA (Serbia)

Description and photo update: 13.08.2019

Baralgetas is a non-narcotic combined remedy that relieves pain and spasms.

Release form and composition

Dosage forms of the drug:

Tablets (10 pcs in blisters, 1 or 10 blisters in a carton pack);
Solution for intramuscular and intravenous administration (in dark glass ampoules, in a cardboard pack of 5 ampoules).

Metamizole sodium - 500 mg;
Pitophenone hydrochloride - 5 mg;
Fenpiverinium bromide - 0.1 mg.

Metamizole sodium has an antipyretic and analgesic effect, fenpiverinium bromide and pitofenone hydrochloride relax the smooth muscles of the internal organs. The action of pitofenone hydrochloride is similar to that of papaverine.

Pharmacological properties

Pharmacodynamics

Baralgetas is a combined analgesic and antispasmodic drug, the components of which mutually reinforce each other's pharmacological action.

Metamizole sodium, which is a derivative of pyrazolone, provides antipyretic, analgesic and weak anti-inflammatory effect due to inhibition of prostaglandin synthesis.

Fenpiverinium bromide has an m-anticholinergic effect, and additionally has a myotropic effect on smooth muscles.

Pitophenone hydrochloride provides a direct myotropic effect on smooth muscles, causing it to relax (papaverine-like effect).

Pharmacokinetics

Metamizole sodium

Metamizole sodium after oral administration is rapidly absorbed from the gastrointestinal tract. In the intestinal wall, the substance is hydrolyzed to form an active metabolite. In the blood, unchanged metamizole sodium is not determined (in a small concentration it is in the blood plasma only after intravenous administration, and it quickly becomes unavailable for determination). As a result of intramuscular injection, a significant proportion of the components of the drug is rapidly absorbed from the injection site. Approximately 50-60% of the substance binds to plasma proteins. When taken in therapeutic doses, it is excreted into breast milk.

Metamizole sodium undergoes intensive biotransformation in the liver. Main metabolites: 4-methylaminoantipyrine, 4-aminoantipyrine, 4-acetylaminoantipyrine, 4-formylaminoantipyrine. Approximately 20 additional metabolites have been identified, including glucuronic acid derivatives. Four major metabolites enter the cerebrospinal fluid. Metamizole sodium is mainly excreted by the kidneys.

Fenpiverinium bromide

Fenpiverinium bromide after oral administration is rapidly absorbed from the gastrointestinal tract. The achievement of the maximum concentration in the blood plasma occurs after 1 hour. It does not penetrate the blood-brain barrier. With urine unchanged, from 32.4 to 40.4% is excreted, and with bile - from 2.3 to 5.3%.

Pitophenone

Pitophenone after oral administration is rapidly absorbed from the gastrointestinal tract. Achieving the maximum concentration in blood plasma occurs after 0.5–1 h. It is rapidly distributed in tissues and organs, does not penetrate the blood-brain barrier. By oxidative reactions it is metabolized in the liver. Excreted with urine. The half-life is 1.8 hours.

Indications for use

The appointment of Baralgetas is also effective for biliary dyskinesia, chronic colitis, algomenorrhea, postcholecystectomy syndrome, diseases of the pelvic organs.

The anesthetic can be used in the short-term therapy of myalgia, sciatica, arthralgia, neuralgia and as an analgesic after operations and diagnostic procedures.

Contraindications

Inhibition of the hematopoietic function of the bone marrow;
Serious renal and hepatic insufficiency;
Tachyarrhythmia, angina pectoris, decompensated chronic heart failure;
Angle-closure glaucoma;
Hyperplasia of the prostate;
Intestinal obstruction;
Collapse;
Hypersensitivity;
Pregnancy, lactation.

Do not administer the drug intravenously to children under 3 months of age or weighing less than 5 kg.

Baralgetas tablets are contraindicated in children under 5 years of age.

With caution, the drug should be taken in case of liver and kidney failure, bronchial asthma, a tendency to low blood pressure, hypersensitivity to anti-inflammatory non-steroidal drugs.

Instructions for use Baralgetas: method and dosage

Pills

Children 5-7 years old: single dose - 1/2 tablet, maximum daily dose - 2 tablets;
Children 8-11 years old: single - 1 / 2 tablets, maximum daily - 4 tablets;
Children 12-14 years old: single - 1 tablet, maximum daily - 6 tablets;
Adolescents over 15 years of age and adults: a single dose - 1-2 tablets, the frequency of administration - 2-3 times a day.

Solution for intramuscular and intravenous administration

Intravenously, the drug is administered to adolescents over 15 years of age and adults with severe and acute colic - in the amount of 2 ml. Baralgetas should be administered slowly, 1 ml over 1 minute. If necessary, the solution can be administered again - after 6-8 hours. Baralgetas is administered intramuscularly 2-3 times a day, 2-5 ml each. Permissible daily dose - 10 ml, duration of treatment - 5 days.

For children, the drug as an anesthetic can be administered intramuscularly and intravenously in accordance with age:

3-11 months: in a volume of 0.1-0.2 ml and only intramuscularly;
1-2 years: 0.2-0.3 ml intramuscularly or 0.1-0.2 ml intravenously;
3-4 years: 0.3-0.4 ml intramuscularly or 0.2-0.3 ml intravenously;
5-7 years: 0.4-0.5 ml intramuscularly or 0.3-0.4 ml intravenously;
8-12 years: 0.6-0.7 ml intramuscularly or 0.5-0.6 ml intravenously;
12-15 years: 0.8-1.0 ml intramuscularly or intravenously.

Before injection, the ampoule with the drug should be held in your hand to warm the solution to room temperature.

Side effects

Allergic reactions: urticaria, angioedema, erythema, epidermal toxic necrolysis, bronchospasm, anaphylactic shock;
Urinary system: impaired renal function, anuria, proteinuria, oliguria, nephritis, discoloration of urine;
Organs of hematopoiesis: agranulocytosis, leukopenia, thrombocytopenia;
Cardiovascular system: lowering blood pressure;
Anticholinergic effects: tachycardia, paresis of accommodation, dryness of the oral mucosa, difficulty urinating, reduced sweating;
Local reactions: with i / m administration, infiltrates are possible at the injection site.

In case of an overdose, vomiting, drowsiness, nausea, epigastric pain, decreased pressure, impaired renal and hepatic function, convulsions appear. In these cases, the patient is washed out the stomach, given activated charcoal to drink.

Overdose

Symptoms: gastralgia, hypothermia, nausea, vomiting, tachycardia, lowering blood pressure, shortness of breath, drowsiness, tinnitus, impaired consciousness, delirium, hemorrhagic syndrome, acute agranulocytosis, oliguria, acute liver and / or kidney failure, paralysis of the respiratory muscles, convulsions .

Treatment: gastric lavage, administration of water-salt solutions, activated charcoal, forced diuresis, hemodialysis. In the case of the development of a convulsive syndrome, intravenous administration of high-speed barbiturates and diazepam is recommended.

special instructions

During the use of Baralgetas, substances containing ethanol should not be consumed.

In the case of prolonged (more than one week) medication, it is necessary to monitor the functional state of the liver and the picture of peripheral blood.

Baralgetas should not be taken to relieve acute abdominal pain until the cause is identified.

You should immediately stop taking the drug if you suspect agranulocytosis, as well as in case of detection of thrombocytopenia.

Lactating women should stop breastfeeding for the duration of treatment.

The use of Baralgetas by children under 5 years of age and by patients receiving cytostatic drugs should be carried out under medical supervision.

For intramuscular injection, a long thin needle should be used.

The probable staining of urine in red color (excretion of a metabolite) has no clinical significance.

Occupations in potentially dangerous types of work, management of complex mechanisms, vehicles must be done with caution, since the speed of mental and physical reactions can be reduced.

Use during pregnancy and lactation

It is forbidden to use Baralgetas during pregnancy (especially during the first trimester and the last 6 weeks).

If it is necessary to use Baralgetas during lactation, it is necessary to stop breastfeeding.

Application in childhood

It is forbidden to use the drug for intravenous administration in patients under the age of 3 months, as well as in the treatment of children weighing up to 5 kg. The use of Baralgetas tablets is contraindicated under the age of 5 years.

For impaired renal function

In case of severe renal insufficiency, Baralgetas should not be used. In renal failure, the drug should be used with caution.

For impaired liver function

In case of severe hepatic insufficiency, Baralgetas should not be used. In hepatic insufficiency, the drug should be used with caution.

Analogues

Analogues of Baralgetas for active active ingredients: Bral, Bralangin, Maksigan, Plenalgin, Revalgin, Renalgan, Spazgan, Spazmalgon, Spazmalin, Spazmoblok, Spazmogard, Trinalgin, Geomag.

Analogues similar in mechanism of action: Akophil, Analgin, Andipal, Antipyrin, Baralgin M, Benalgin, Quintalgin, Pentabufen, Pentalgin, Santoperalgin, Sedal-M, Sedalgin-Neo, Tempalgin, Tempanginol, Tetralgin, Quatrox.

Terms and conditions of storage

Store in a dry place protected from light, at room temperature not exceeding 25 °C.

Shelf life - 5 years.

"Baralgetas", what does this combined pain reliever, antispasmodic help from? The drug has a pronounced anti-inflammatory and antipyretic effect. The drug "Baralgetas" instructions for use suggests using it for colic, spasms, myalgia.

Composition and form of release

Produced in tablets and solution for injection into a vein or muscle tissue. The medicine "Baralgetas", from which it helps with inflammation and fever, contains the following active elements:

Fenpiverinium bromide - 0.1 mg.
Pitophenone hydrochloride - 5 mg.
Metamizole sodium or analgin - 0.5 g.

Also, the composition of the drug includes excipients. It is sold in blisters and ampoules.

Pharmacological properties

The effectiveness of the drug "Baralgetas", from which it helps with pain symptoms, is due to the mutual action of its active components, which reinforce each other.

Analgin has analgesic and thermoregulatory effects. Pitophenone hydrochloride has a mildly relaxing effect on smooth muscles. Fenpiverinium bromide also complements the relaxing effect of pitofenone and has m-anticholinergic properties. In addition, the drug has a pronounced anti-inflammatory effect.

Injections, tablets "Baralgetas": what helps the medicine

Indications for use include pain of varying intensity, disturbing as a result of spastic conditions of the smooth muscles of the internal organs:

chronic colitis;
dyskinesia of the excretion of bile;
renal colic;
postcholecystectomy syndrome;
algomenorrhea;
biliary colic;
spasms of the genitourinary system;
intestinal colic;
pain in the pelvic area.

What else does the medicine help with? As a non-long-term therapy, the drug is prescribed for:

sciatica;
arthralgia;
myalgia;
neuralgia.

The tool is used to relieve pain along with other medicines when performing diagnostic and surgical measures.

Contraindications

The instruction prohibits the use of "Baralgetas" when:

decompensated CHF;
tachyarrhythmias;
angle-closure glaucoma;
prostatic hyperplasia;
kidney failure;
intestinal obstruction;
hypersensitivity to the composition of the drug "Baralgetas", from which these tablets and injections can cause allergies;
liver failure;
severe angina;
lack of glucose-6-phosphate dehydrogenase;
megacolone;
collapse;
at the initial and final stages of pregnancy;
during the period of breastfeeding.

Do not prescribe tablets "Baralgetas" to children under 5 years old, intravenous administration - to babies up to 3 months or weighing up to 5 kg.

Caution during therapy is required for patients with low blood pressure, the aspirin triad, asthmatics, people with intolerance to NSAIDs.

The drug "Baralgetas": instructions for use

The annotation states that the drug is used orally or parenterally. This applies to the form in tablets and injection solution, respectively.

Instructions for use of tablets

Adults and adolescents over 15 years of age are prescribed 6 tablets per day. The total dosage is divided into 2-3 times, taking 1-2 tablets. The medicine is recommended to be taken after meals with a sufficient amount of liquid. It shouldn't be bitten.

Children are given pills in a minimum amount, which depends on their age:

5-7 years - up to 2 tablets;
8-11 - up to 4 tablets;
12-14 - up to 6 tablets.

The use of injections "Baralgetas"

Adults with acute colic need to inject 2 ml of the drug into a vein. The injection is done slowly at a rate of 1 minute per 1 ml. The second procedure is carried out after 6-8 hours.

Baralgetas injections into the muscle are performed in a volume of 2-5 ml 2-3 times a day. The daily dosage should not exceed 10 ml. Treatment takes up to 5 days.

For children, the dosage is set by the doctor based on the child's body weight and age:

3-11 months, weight 5-8 kg - 0.1-0.2 ml (injections are made only in the muscle;
1-2 years - 0.1-0.2 ml intravenously or 0.2-0.3 ml into the muscle;
3-4 years - intramuscularly 0.3-0.4 ml or 0.2-0.3 ml into a vein;
5-7 years - 0.3-0.4 ml into a vein, 0.4-0.5 ml - into muscle tissue;
8-12 years - 0.5-0.6 ml IV or 0.6-0.7 ml IM;
12-15 years 0.8 to 1 ml IV or IM.

Side effects

The drug "Baralgetas", instructions and patient reviews confirm this, cause the following adverse reactions of the body:

change in the color of urine;
thrombocytopenia;
erythema;
dryness of the oral mucosa;
angioedema;
reduced sweating;
bronchospasm;
oliguria;
toxic necrolysis;
difficulty urinating;
lowering blood pressure;
hives;
nephritis;
anuria;
leukopenia;
tachycardia;
anaphylactic shock;
infiltrates at the injection site;
agranulocytosis;
proteinuria;
accommodation paresis;
impaired renal function.

If the allowable dosage is exceeded, nausea, drowsiness, convulsions, vomiting, and a decrease in pressure may occur. It is required to perform a gastric lavage, drink activated charcoal.

Analogues and synonyms

You can replace the medicine "Baralgetas" with analogues:

"Revalgin".
"Andipal".
"Pentalgin".
"Spazgan".
"Bral."
"Baralgin".
Spasmalin.
Spazmalgon.
"Sedal-M".
"Sedalgin".
"Maxigan".
"Analgin".
"Benalgin".

Baralgetas belongs to the category of combined drugs that combine antispasmodic and analgesic effects. The drug is used to relieve pain of various origins.

With myalgia, neuralgia and arthralgia, the medication is used as an emergency remedy. At the stage of postoperative recovery, Baralgetas can be prescribed as an auxiliary drug to alleviate the patient's condition. The action of the analgesic extends to the digestive, genitourinary and other systems of the body. In some pathological processes, the medication is contraindicated for taking. Baralgetas is used in pediatrics, but it also has age restrictions.

You can get acquainted with the reviews of people about this tool at the end of the article.

1. Instruction

This manual contains important information that should be read carefully. This must be done in order to avoid errors in the future.

pharmachologic effect

The effectiveness of Bralgetas in the treatment of pathologies accompanied by pain is due to the combination of certain components in its composition. Each of the active active substances has its own pharmacological properties, which are enhanced by auxiliary elements. The drug acts on the area of inflammation, relaxes the smooth muscle layer and inhibits the synthesis of prostaglandins. Pain relief occurs within thirty minutes.

Pharmacological properties:

m-anticholinergic action;
antipyretic effect;
reduction of symptoms of the inflammatory process;
papaverine-like action on smooth muscles;
relief of pain syndromes of various origins.

Indications

The use of Baralgetas is justified in the weak. as well as moderate painful sensations that are caused by muscle spasms, for example, ureters, biliary and intestinal colic. This remedy can be drunk with biliary dyskinesia, algomenorrhea, chronic colitis, pelvic diseases, and postcholecystectomy syndrome.

The tool can also be used for short-term therapy of arthralgia, myalgia and ischialgia. In addition, very often the remedy is used after surgery to relieve pain.

Mode of application

The required dosage, as well as the duration of treatment, can only be selected by the attending physician. Pills. Adults should take no more than 2 tablets 2 times / day.

For children, the dosage is selected based on the age of the child and his weight:

5-7 years old - the dosage is no more than 1/2 tablet, the maximum dosage per day can be no more than 2 pcs;
8-11 years old - the dosage can be 1/2 tablet, a child can be given no more than 4 pcs per day;
12-14 years - the dose should be no more than 1 tablet at a time. No more than 6 tablets can be given per day.

Solution. The drug in injectable form can be administered to adolescents from 15 years of age, as well as adults at a dosage of 2 ml. Intravenously, the drug must be administered very slowly, i.e. 1 ml for 1 min. If required, the solution is re-introduced after 6 hours. When administered intramuscularly, the drug Baralgetas is administered 2-3 times in 2-5 ml. The maximum permitted dosage per day is 10 ml.

Treatment can last 5 days.

To select the dosage for children, it is important to take into account the age of the baby:

Before the injection, the ampoule needs to be slightly warmed up in the hand.

Release form

In pharmacies, you can find 2 forms of drug release:

Pills;
Solution.

The composition of the tablet/solution includes metamizole sodium, fenpiverinium bromide, and pitofenone hydrochloride.

Interaction

The solution for injection should never be combined with other drugs. Simultaneous reception with alcohol enhances the effect of ethanol. Co-administration with chlorpromazine can provoke the development of hyperthermia.

Contraceptives, antidepressants and allopurine increase the toxicity of Baralgetas. With the simultaneous administration of Baralgetas and cyclosporine, the concentration of the second in human blood decreases several times.

The effectiveness of the tool is increased several times: codeine, propranolol.

2. Side effects

Angioedema, shock, necrolysis, erythema, bronchospasm;
Anuria, discoloration of urine (this does not affect the analyzes in any way), nephritis, proteinuria, and also oliguria;
Thrombocytopenia, agranulocytosis and leukopenia;
A sharp decrease in blood pressure;
Tachycardia, dry mouth, decreased/increased sweating, paresis of accommodation.

Contraindications

This drug should not be taken in conditions such as:

Allergy to the components that make up the product;
Severe form of renal / hepatic insufficiency;
Angina pectoris, glaucoma, intestinal obstruction, hyperplasia, tachyarrhythmia;
Collapse and also megacolon.

In addition, for intravenous administration of the solution, a contraindication is the child's age of the baby (up to 3 months), and for tablets - 5 years.

In addition, the remedy should be administered carefully if there is asthma, the "aspirin" triad.

Pregnancy

During pregnancy, it is better not to use this remedy. This is due to the fact that the drug can have a negative effect on the fetus.

During the period of breastfeeding, the drug should also be abandoned. This is due to the fact that the medicine can have a negative effect on the baby. If it is impossible to refuse the reception, then it is necessary to decide on the termination of natural feeding.

3. Special instructions

Influence on the ability to drive vehicles and control mechanisms

Baralgetas can reduce the speed of psychomotor reactions. During the period of therapy, it is recommended to exclude potentially hazardous activities that involve maintaining concentration. Driving a car should also be avoided.

Pregnancy and lactation

The manufacturer refers pregnancy to the list of contraindications for the use of Baralgetas. It is strictly forbidden to take the drug in the first six weeks of the gestation period. The medication is not compatible with the lactation period. For the duration of therapy, breastfeeding should be discontinued.

Application in childhood

Baralgetas is used in pediatrics, but has age restrictions. In the form of a solution, the drug is prohibited for children under three months old and weighing less than five kilograms. Tablets can only be taken from the age of five.

For disorders of the kidneys

The instruction warns against self-administration of Baralgetas for kidney dysfunctions. In the presence of such pathologies, the drug is used with caution. Severe renal failure is considered an absolute contraindication for the use of an analgesic.

For disorders of the liver

Severe liver failure is a contraindication for the use of Baralgetas. For other liver dysfunctions, the drug is recommended to be used with caution.

Terms of dispensing from pharmacies

The sale of Baralgetas in pharmacies is carried out by prescription.

4. Storage method

The drug should be stored at room temperature in a place where children will not have access. The place must also be protected from moisture and light.

If all conditions are met, then both dosage forms of the drug can be stored for 5 years. After the expiration date has passed, it is forbidden to use the drug further.

5. Price

The exact cost of the drug Baralgetas should be found in pharmacies. Prices can vary significantly depending on the country and region.

Russia

For the drug Baralgetas in Russia, on average, you will have to pay 225 rubles.

Ukraine

On average, you will have to pay 68 hryvnia for a medicine.

Video on the topic: Massage for intestinal colic in newborns and infants

; 5 mg pitofenone hydrochloride ; 100 mcg fenpiverinium bromide - active ingredients.

Ampoule includes: 2500 mg metamizole sodium ; 2 mg pitofenone hydrochloride ; 20 mcg fenpiverinium bromide - active ingredients.

Release form

The drug Baralgetas is available in the form of tablets of 10 or 100 pieces in one package and in the form of an injection solution in 5 ml ampoules, 5 pieces in one package.

pharmachologic effect

Spasmolytic and analgesic.

Pharmacodynamics and pharmacokinetics

Baralgetas, due to the combined effect of active ingredients that enhance each other's action, is a combined antispasmodic And analgesic drug.

Action pitofenone hydrochloride characterized by direct myotropic (relaxing) effect on smooth muscle . Derivative pyrazolone - metamizole sodium ( ) shows a pronounced analgesic and less pronounced anti-inflammatory And antipyretic action. M-anticholinergic action fenpiverinium bromide complemented by the effect of relaxation of smooth muscles.

Indications for use

Tablets and injections of the drug Baralgetas are prescribed for the manifestation of mild or moderate pain syndrome , due to spasm of smooth muscles internal organs, including: biliary tract, algomenorrhea , bladder and ureter, biliary colic , postcholecystectomy syndrome, intestinal colic , chronic, as well as painful conditions of the pelvic organs.

As a short-term drug for: arthralgia , myalgia , sciatica .

As an adjuvant for pain syndrome triggered by diagnostic and/or surgical procedures.

Contraindications

hypersensitivity to one or the sum of the ingredients of the drug (also to derivatives pyrazolone );
severe pathologies of the liver and / or kidneys;
suppression bone marrow hematopoiesis ;
flaw glucose-6-phosphate dehydrogenase ;
CHF (decompensated);
severe course;
tachyarrhythmias ;
angle-closure glaucoma;
intestinal obstruction;
(with clinical symptoms);
collapse ;
megacolon ;
age up to 5 years for the tablet form and up to 3 months (or with a weight of less than 5 kg) for intravenous injections;
periods lactation And pregnancy .

Take with caution:

at ;
with renal / hepatic insufficiency;
with a predisposition to hypotension ;
with increased sensitivity to NSAIDs ;
with acute or developed due to the intake NSAIDs .

Side effects

Hematopoietic system:

thrombocytopenia ;
leukopenia .

Urinary system:

oliguria ;
weakening of kidney function;
interstitial nephritis ;
red coloration of urine.

The cardiovascular system:

lowering blood pressure .

Allergic manifestations:

hives (among other things, on the mucous membrane of the nasopharynx and conjunctiva);
bronchospastic syndrome;
Lyell's syndrome, as well as Stevens-Johnson's;

dryness in the mouth;
paresis of accommodation ;
decreased sweating;
difficulty urinating ;
with intramuscular injections, infiltrates are possible.

Application instruction of Baralgetas (Way and dosage)

The instruction for Baralgetas involves taking the drug orally (in the form of tablets) and parenterally (in the form of an injection solution).

The maximum dose per day for patients over 15 years of age is 6 tablets; 2-3 times a day, 1-2 tablets of Baralgetas are recommended. Instructions for use advises swallowing the tablets whole (preferably after meals) and drinking water. An increase in the daily dose is possible only on the recommendation of a doctor.

For children, the appointment of Baralgetas is possible only by a doctor and preferably in the minimum daily recommended doses, which should not exceed 2 tablets at the age of 5-7 years; 4 tablets at the age of 8-11 years and 6 tablets at the age of 12-14 years.

With parenteral (in / in, in / m) administration of the drug, it is recommended for patients after 15 years of age, in case of severe and acute colic, intravenous administration of 2 ml of Baralgetas. The introduction is carried out slowly, 1 ml for 60 seconds (it is possible to repeat the injection after 6-8 hours). V / m injections are carried out at a dose of 2-5 ml with a frequency of 2-3 times in 24 hours. It is not recommended to inject more than 10 ml per day. Duration of therapy - no more than 5 days.

The calculation of the pediatric injection dose takes into account the age and weight of the patient:

at the age from 3 to 11 months (5-8 kg), only intramuscular administration at a dose of 0.1-0.2 ml is possible;
at the age from 1 to 2 years (9-15 kg), intravenous injection of 0.1-0.2 ml and intramuscular injection of 0.2-0.3 ml are allowed;
at the age from 3 to 4 years (16-23 kg) it is possible to inject 0.2-0.3 ml in/in and 0.3-0.4 ml in/m;
at the age of 5 to 7 years (24-30 kg) recommend intravenous injection of 0.3-0.4 ml and intramuscular injections of 0.4-0.5 ml;
at the age of 8 to 12 years (31-45 kg), an intravenous dose of 0.5-0.6 ml and an intramuscular dose of 0.6-0.7 ml are indicated;
at the age of 12 to 15 years in / in and / m, the dose can be from 0.8 to 1 ml.

Injection solution, especially before the / in the introduction, it is recommended to warm in the hand.

Overdose

With an overdose of Baralgetas, it can develop, downgrade HELL , confusion, pain in the epigastric region, nausea , liver and kidney disorders, and convulsions .

Overdose therapy is conventional, including gastric lavage, acceptance and symptomatic treatment.

Interaction

Baralgetas injection solution is pharmaceutically incompatible with other drugs.

M-anticholinergic action is enhanced when combined with butyrophenones , H1 blockers (histamine), phenothiazines , , tricyclic antidepressants And quinidine .

Baralgetas increases effects ethanol .

Joint reception with derivatives phenothiazine (Chlorpromazine ) can cause the development hyperthermia pronounced character.

The toxicity of the drug is increased tricyclic antidepressants , And .

Barbiturates , Phenylbutazone and other inducers of liver enzymes reduce the effectiveness of Baralgetas, and anxiolytic And sedatives drugs increase.

When taking Baralgetas, such drugs as colloidal are contraindicated blood substitutes and radiopaque agents.

Joint reception cytostatics And Thiamazole increase the possibility of leukopenia .

The effects of Baralgetas are enhanced when taken , and blockers of H2-histamine receptors.

Terms of sale

Tablets and ampoules of Baralgetas are sold with a prescription.

Storage conditions

All dosage forms of the drug should be stored at temperatures up to 25 ° C.

In this article, you can read the instructions for using the drug Baralgetas. Reviews of site visitors - consumers of this medicine, as well as opinions of doctors of specialists on the use of Baralgetas anesthetic in their practice are presented. We kindly ask you to actively add your reviews about the drug: the medicine helped or did not help get rid of the disease, what complications and side effects were observed, perhaps not declared by the manufacturer in the annotation. Analogues of Baralgetas in the presence of existing structural analogues. Use for the treatment of headache and toothache, neuralgia in adults, children, as well as during pregnancy and lactation. The composition of the drug.

Baralgetas- a combined analgesic and antispasmodic agent, the combination of the components of the drug leads to a mutual enhancement of their pharmacological action.

Metamizole sodium - a derivative of pyrazolone, has an analgesic and antipyretic effect.

Pitophenone hydrochloride has a direct myotropic effect on smooth muscles (papaverine-like action).

Fenpiverinium bromide has an m-anticholinergic effect and has an additional myotropic effect on smooth muscles.

Compound

Metamizole sodium + Pitophenone hydrochloride + Fenpiverinium bromide + excipients.

Indications

Pain syndrome (mild or moderate) with spasms of smooth muscles of internal organs: renal colic, spasm of the ureter and bladder; biliary colic, intestinal colic; biliary dyskinesia, postcholecystectomy syndrome, chronic colitis; algomenorrhea, diseases of the pelvic organs.

For short-term treatment: arthralgia, myalgia, neuralgia, sciatica.

As an auxiliary drug: pain syndrome after surgical interventions and diagnostic procedures.

Release form

Tablets 500 mg.

Solution for intravenous and intramuscular administration (injections in ampoules for injection).

Instructions for use and dosing regimen

Pills

Inside: adults and adolescents over 15 years old: 1-2 tablets 2-3 times a day, without chewing, with a small amount of liquid.

Children 12-14 years old: single dose - 1 tablet, maximum daily dose - 6 tablets (1.5 tablets 4 times a day), 8-11 years old - 0.5 tablets, maximum daily dose - 4 tablets (1 tablet 4 times a day) , 5-7 years - 0.5 tablets, the maximum daily dose - 2 tablets (0.5 tablets 4 times a day).

Ampoules

Parenterally (intravenously, intramuscularly).

Adults and adolescents over 15 years of age with acute severe colic are injected intravenously slowly (1 ml over 1 minute), 2 ml; if necessary, re-introduce after 6-8 hours. V / m - 2-5 ml of the solution 2-3 times a day. The daily dose should not exceed 10 ml. Duration of treatment - no more than 5 days.

Dose calculation for children with intravenous and intramuscular administration: 3-11 months (5-8 kg) - only intramuscularly - 0.1-0.2 ml; 1-2 years (9-15 kg) - in / in - 0.1-0.2 ml, in / m - 0.2-0.3 ml; 3-4 years (16-23 kg) - in / in - 0.2-0.3, in / m - 0.3-0.4 ml; 5-7 years (24-30 kg) - in / in - 0.3-0.4 ml, in / m - 0.4-0.5 ml; 8-12 years (31-45 kg) - in / in - 0.5-0.6 ml, in / m - 0.6-0.7 ml; 12-15 years - in / in and / m - 0.8-1 ml.

Before the introduction of the injection solution, it should be warmed in the hand.

Side effect

urticaria (including on the conjunctiva and mucous membranes of the nasopharynx);
angioedema;
malignant exudative erythema (Stevens-Johnson syndrome);
toxic epidermal necrolysis (Lyell's syndrome);
bronchospastic syndrome;
anaphylactic shock;
impaired renal function;
oliguria;
anuria;
proteinuria;
interstitial nephritis;
urine staining red;
decrease in blood pressure;
thrombocytopenia, leukopenia, agranulocytosis (may be manifested by the following symptoms: unmotivated rise in temperature, chills, sore throat, difficulty swallowing, stomatitis, as well as the development of vaginitis or proctitis);
dry mouth;
decreased sweating;
accommodation paresis;
tachycardia;
difficulty urinating;
with i / m administration, infiltrates are possible at the injection site.

Contraindications

hypersensitivity (including to pyrazolone derivatives);
oppression of bone marrow hematopoiesis;
severe hepatic and / or renal failure;
deficiency of glucose-6-phosphate dehydrogenase;
tachyarrhythmias;
severe angina;
decompensated chronic heart failure;
angle-closure glaucoma;
prostatic hyperplasia (with clinical manifestations);
intestinal obstruction;
megacolon;
collapse;
pregnancy (especially in the 1st trimester and in the last 6 weeks);
lactation period.

For intravenous administration - infancy (up to 3 months) or body weight less than 5 kg. For tablets - children's age (up to 5 years).

Use during pregnancy and lactation

Contraindicated in pregnancy (especially in the 1st trimester and in the last 6 weeks).

Use in nursing mothers requires cessation of breastfeeding.

Use in children

Contraindications for intravenous administration - infancy (up to 3 months) or body weight less than 5 kg; for tablets - children's age (up to 5 years).

Treatment of children under 5 years of age should be carried out only under medical supervision.

special instructions

With prolonged (more than a week) treatment, it is necessary to control the pattern of peripheral blood and the functional state of the liver.

If agranulocytosis is suspected or if thrombocytopenia is present, the drug should be discontinued.

It is unacceptable to use for the relief of acute pain in the abdomen (until the cause is clarified).

Intolerance is very rare, but the risk of developing anaphylactic shock after intravenous administration of the drug is relatively higher than after oral administration. Patients with atopic bronchial asthma and hay fever have an increased risk of developing allergic reactions.

Parenteral administration should be used only in cases where oral administration is not possible (or absorption from the gastrointestinal tract is impaired). Special care is required when administering more than 2 ml of solution (risk of a sharp decrease in blood pressure). In / in the injection should be carried out slowly, in the "lying" position and under the control of blood pressure, heart rate and respiratory rate.

In the treatment of children under 5 years of age and patients receiving cytostatics, metamizole sodium should only be taken under medical supervision.

For intramuscular injection, a long needle must be used.

It is possible to stain urine red due to the release of a metabolite (it has no clinical significance).

Influence on the ability to drive vehicles and control mechanisms

During treatment, caution should be exercised for drivers of vehicles and persons engaged in potentially hazardous activities that require quick physical and mental reactions.

drug interaction

Solution for injection is pharmaceutically incompatible with other drugs.

With the joint appointment of histamine with H1-blockers, butyrophenones, phenothiazines, tricyclic antidepressants, amantadine and quinidine, it is possible to increase the m-anticholinergic action.

Enhances the effects of ethanol (alcohol); simultaneous use with chlorpromazine or other phenothiazine derivatives can lead to the development of severe hyperthermia.

Tricyclic antidepressants, oral contraceptives and allopurinol increase drug toxicity.

Phenylbutazone, barbiturates and other inducers of hepatic enzymes, when administered simultaneously, reduce the effectiveness of metamizole sodium.

Sedative and anxiolytic drugs (tranquilizers) enhance the analgesic effect of metamizole sodium.

Radiopaque drugs, colloidal blood substitutes and penicillin should not be used during treatment with drugs containing metamizole sodium.

With the simultaneous appointment of cyclosporine, the concentration of the latter in the blood decreases.

Metamizole sodium, displacing oral hypoglycemic drugs, indirect anticoagulants, corticosteroids and indomethacin from the connection with the protein, can increase the severity of their action.

Thiamazole and cytostatics increase the risk of developing leukopenia.

The effect is enhanced by codeine, H2-histamine receptor blockers and propranolol (slows down the inactivation of metamizole sodium).

Analogues of the drug Baralgetas

Structural analogues for the active substance:

took;
Bralangin;
Geomage;
Maxigan;
Plenalgin;
Revalgin;
Renalgan;
Spazgan;
Spazmalgon;
Spasmalin;
Spasmoblock;
Trinalgin.

Analogues by pharmacological group (pyrazolones in combinations):

Analgin quinine;
Andipal;
Antigrippin SARS;
Benalgin;
took;
Bralangin;
Geomage;
Maxigan;
Otipax;
Otirelax;
Pentabufen;
Pentalgin;
Piralgin;
Plenalgin;
Revalgin;
Renalgan;
Santoperalgin;
Santotitralgin;
Sedal M;
Sedalgin Neo;
Sedalgin Plus;
Spazgan;
Spazmalgon;
Spasmalin;
Spazmil M;
Spasmoblock;
Tempalgin;
Tempanginol;
Tetralgin;
Trinalgin;
Folicap.

In the absence of analogues of the drug for the active substance, you can follow the links below to the diseases that the corresponding drug helps with and see the available analogues for the therapeutic effect.